A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies

Mise à jour : Il y a 5 ans
Référence : NCT00405743

Femme et Homme

Extrait

Patients with refractory or relapsed hematologic malignancies will receive CP-4055 intravenously(IV) on Day 1-5 every three weeks until complete response or disease worsening/progressing


Critère d'inclusion

  • hematologic malignancies ,AML


Liens